Association of Transcatheter Left Atrial Appendage Occlusion with Acute Changes in Left Atrial Pressure: An Invasive Hemodynamic Study.

Left atrial appendage occlusion atrial fibrillation heart failure left atrial pressure peridevice leak

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
14 Feb 2024
Historique:
received: 15 11 2023
revised: 29 01 2024
accepted: 11 02 2024
medline: 17 2 2024
pubmed: 17 2 2024
entrez: 16 2 2024
Statut: aheadofprint

Résumé

The hemodynamic effects of transcatheter left atrial appendage occlusion (LAAO) remain unclear. We sought to assess the effect of LAAO on invasive hemodynamics and their correlation with clinical outcomes. We recorded mean left atrial pressure (mLAP) before and after device deployment. We assessed: (a) the prevalence and predictors of mLAP increase post-deployment; (b) the association between significant mLAP increase post-deployment and 45-day peridevice leak (PDL); (c) the association between mLAP increase and heart failure (HF) hospitalization. Significant mLAP increase was defined as one equal to or greater than the mean percentage increase in mLAP post-deployment (≥28%). We included 302 patients (36.4% female; mean age, 75.8±9.5 years). Post-deployment, mLAP increased in 48.0% of patients, 38.0% of whom experienced significant mLAP increase. Independent predictors of mLAP increase were baseline mLAP ≤14 mmHg, non-paroxysmal atrial fibrillation, and age (odds ratios: 3.66; 95%CI 2.21-6.05, 1.81; 95%CI 1.08-3.02, and 0.85 (per 5 years); 95%CI 0.73-0.99, respectively). Significant mLAP increase was an independent predictor of 45-day PDL (OR: 2.55; 95%CI 1.04-6.26). There was no association between mLAP increase and HF hospitalization. MLAP acutely rises in 48% of patients post-deployment, although this is not associated with increased HF hospitalizations. Patients with significant increase in mLAP post-deployment are more likely to develop PDL at 45 days, albeit most leaks were small (<5 mm). These findings suggest that mLAP increase post-deployment is not associated with major safety concerns. Additional studies are warranted to explore the long-term hemodynamic effects of LAAO.

Sections du résumé

BACKGROUND BACKGROUND
The hemodynamic effects of transcatheter left atrial appendage occlusion (LAAO) remain unclear.
OBJECTIVE OBJECTIVE
We sought to assess the effect of LAAO on invasive hemodynamics and their correlation with clinical outcomes.
METHODS METHODS
We recorded mean left atrial pressure (mLAP) before and after device deployment. We assessed: (a) the prevalence and predictors of mLAP increase post-deployment; (b) the association between significant mLAP increase post-deployment and 45-day peridevice leak (PDL); (c) the association between mLAP increase and heart failure (HF) hospitalization. Significant mLAP increase was defined as one equal to or greater than the mean percentage increase in mLAP post-deployment (≥28%).
RESULTS RESULTS
We included 302 patients (36.4% female; mean age, 75.8±9.5 years). Post-deployment, mLAP increased in 48.0% of patients, 38.0% of whom experienced significant mLAP increase. Independent predictors of mLAP increase were baseline mLAP ≤14 mmHg, non-paroxysmal atrial fibrillation, and age (odds ratios: 3.66; 95%CI 2.21-6.05, 1.81; 95%CI 1.08-3.02, and 0.85 (per 5 years); 95%CI 0.73-0.99, respectively). Significant mLAP increase was an independent predictor of 45-day PDL (OR: 2.55; 95%CI 1.04-6.26). There was no association between mLAP increase and HF hospitalization.
CONCLUSION CONCLUSIONS
MLAP acutely rises in 48% of patients post-deployment, although this is not associated with increased HF hospitalizations. Patients with significant increase in mLAP post-deployment are more likely to develop PDL at 45 days, albeit most leaks were small (<5 mm). These findings suggest that mLAP increase post-deployment is not associated with major safety concerns. Additional studies are warranted to explore the long-term hemodynamic effects of LAAO.

Identifiants

pubmed: 38365125
pii: S1547-5271(24)00193-0
doi: 10.1016/j.hrthm.2024.02.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Hasan S Alarouri (HS)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Gerardo V Lo Russo (GV)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Alejandra Chavez Ponce (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Abdul-Rahman Akkawi (AR)

Department of Internal Medicine, University of Kansas Medical Center, Wichita, KS.

Abdulah Mahayni (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Agata Sularz (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Trevor Simard (T)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Gurpreet Singh (G)

Department of Cardiovascular Medicine, Mayo Clinic Health System, Eau Claire, WI.

William R Miranda (WR)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Mohamad Alkhouli (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: Alkhouli.Mohamad@mayo.edu.

Classifications MeSH